Actinium Pharmaceuticals, Inc. ATNM
As ofNov 20, 2026, 2:51 PM EST
- YTD
- -22.51%
- 1 year
- -18.31%
- Market cap
- 33.13M
- Revenue (ttm)
- 81.00K
- EPS (ttm)
- 0.43
- Shares out
- 31.20M
- P/E ratio
- 2.45
- Forward P/E
- -1.77
- YTD return
- -22.51%
- 1-year return
- -18.31%
- Volume
- 232.25K
- Avg volume
- 191.69K
- Open
- 1.07
- Previous close
- 1.07
- Day's range
- 1.00 – 1.10
- 52-week range
- 0.735 – 1.72
- Beta
- 0.15
- Price target
- 5.00 (+374.5%)
Key statistics
- 50-day average
- 1.55
- 200-day average
- 4.86
- Enterprise value
- -32.78M
- Price / sales
- 469.86
- Price / book
- 0.93
- Free cash flow
- -20.06M
- Total cash
- 86.04M
- Total debt
- 1.85M
- Return on equity
- -87.96%
- Short % of float
- 4.66%
Fundamental scorecard
12 of 25 checks passed on ATNM’s reported financials
12of 25 checks passed
- Value 3 of 5
- Growth 2 of 5
- Profitability 3 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.35 | -0.37 | -0.02 | -5.71% |
| Aug 5, 2024 | Jun 1, 2024 | -0.48 | -0.38 | +0.10 | +20.83% |
| Apr 26, 2024 | Mar 1, 2024 | -0.42 | -0.31 | +0.11 | +26.19% |
| Mar 29, 2024 | Dec 1, 2023 | -0.54 | -0.33 | +0.21 | +38.89% |
| Nov 2, 2023 | Sep 1, 2023 | 0.00 | -0.49 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.50 | -0.58 | -0.08 | -16.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 6, 2024 | Maxim Group | main | Buy | Buy |
| Jul 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- actiniumpharma.com
News
HC Wainwright & Co. Reiterates Buy on Actinium Pharmaceuticals, Maintains $4 Price Target
Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress
12 Health Care Stocks Moving In Wednesday's Pre-Market Session Actinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026
Why Is Actinium Pharmaceuticals Stock Gaining Tuesday? Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine
Your note
Sign in to keep a note on ATNM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.21% | 1,938,558 | 2.37M | Sep 29, 2024 |
| Vanguard Group Inc | 5.21% | 1,625,000 | 1.98M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.20% | 686,153 | 837.11K | Sep 29, 2024 |
| State Street Corporation | 1.93% | 602,649 | 735.23K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.45% | 453,694 | 553.51K | Sep 29, 2024 |
| AQR Capital Management, LLC | 1.15% | 359,353 | 438.41K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.01% | 938,633 | 1.15M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.49% | 778,303 | 949.53K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.36% | 424,314 | 517.66K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.01% | 316,153 | 385.71K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.86% | 269,621 | 328.94K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.57% | 178,041 | 217.21K | Oct 30, 2024 |
